LoadingLoadingLoadingNet selling: insiders sold $5.3M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsEach bar is 100% of that source’s money. The notch marks an even split.
Lean is the direction of the latest moves. Descriptive, not advice.
Buys/Adds (3)
AQR
$99.3M
added
Millennium
$61.0M
added
Citadel
$24.5M
added
No tracked top-trader positions in RMD as of Oct 24, 04:48 UTC.
Hyperliquid positioning - not every stock is covered
Last report
Aug 6, 2026
Period ending
Jun 30, 2026
Earnings per share
$2.89 expected
Revenue
Financial statements: Alpha Vantage
Estimates as of Oct 24, 2026
EPS expected
$2.62 to $2.76
Revenue expected
14 analysts
Last 30 days
Analysts cutting estimates
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / income | Surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 6, 2026 | $2.95 / $2.89Yahoo Finance | +1.98% beat | $1.46B No estimate | Unavailable |
| Mar 31, 2026 | Apr 30, 2026 | $2.86 / $2.80Yahoo Finance | +2.15% beat | $1.43B No estimate | Unavailable |
| Dec 31, 2025 | Jan 29, 2026 | $2.81 / $2.72Yahoo Finance | +3.15% beat | $1.42B No estimate | Unavailable |
| Sep 30, 2025 | Oct 30, 2025 | $2.55 / $2.50Yahoo Finance | +2.05% beat | $1.34B No estimate | Unavailable |
| Jun 30, 2025 | Jul 31, 2025 | $2.55 / $2.48Alpha Vantage | +2.82% beat | $1.35B No estimate | Unavailable |
| Mar 31, 2025 | Apr 23, 2025 | $2.37 / $2.36Alpha Vantage | +0.42% in line | $1.29B No estimate | Unavailable |
| Dec 31, 2024 | Jan 30, 2025 | $2.43 / $2.31Alpha Vantage | +5.19% beat | $1.28B No estimate | Unavailable |
| Sep 30, 2024 | Oct 24, 2024 | $2.20 / $2.04Alpha Vantage | +7.84% beat | $1.22B No estimate | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue and income use company releases, SEC filings, Alpha Vantage or Yahoo Finance. Non-USD revenue carries its currency code. Comparisons require a paired release estimate.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $1.34B | $1.42B | $1.43B | $1.46B |
| Cost of what it sold | $514.8M | $538.1M | $540.4M | $602.4M |
| Gross profit | $820.8M | $884.7M | $891.0M | $861.2M |
| What it spent | ||||
| Research and development | $87.3M | $91.0M | $94.3M | $105.7M |
| Sales and admin | $259.2M | $278.4M | $285.7M | $296.3M |
| Other operating costs | $27.8M | $17.7M | $11.2M | $10.5M |
| Total operating expenses | $374.3M | $387.1M | $391.2M | $412.5M |
| What was left | ||||
| Operating profit | $446.5M | $497.6M | $499.8M | $448.7M |
| Interest on debt | $8.8M | $7.9M | $12.3M | $20.9M |
| Profit before tax | $446.8M | $496.1M | $502.3M | $474.2M |
| Tax | $98.3M | $103.6M | $103.6M | $90.7M |
| Net profit | $348.5M | $392.6M | $398.7M | $383.4M |
| EBITDA | $513.3M | $566.4M | $583.6M | $503.8M |
This stock is in a strong uptrend, and looks overbought after a fast run-up.
Trend
Strong uptrend
85 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage leans bullish
ResMed Inc. Estimates – NYSE:RMD
NeutralOct 23Mettler-Toledo International, I (MTD) Stock Forecasts
NeutralOct 23ResMed Inc. (RMD) Stock forecasts
NeutralOct 23Learn Why The Bull Case For ResMed (RMD) Could Change Following U.S. Mask Launch
Leans bullishOct 23ResMed Inc. (RMD) Stock forecasts
BullishOct 23Zimmer Biomet Holdings, Inc. (ZBH) Stock forecasts
NeutralOct 22IDEXX Laboratories, Inc. (IDXX) Stock Forecasts
NeutralOct 22Zimmer Biomet Holdings, Inc. (ZBH) Stock forecasts
NeutralOct 22
